// App-Quantinova.ai

: Minimal Residual Disease Negativity after Blinatumomab Is Predictive of Survival in B-Cell Acute Lymphoblastic Leukemia: Data from a Real-Life Study

Researchers

Presenter

  • Salvatore Leotta

Principal Investigators

  • Andrea Duminuco

  • Antonino Mule

  • Stefania Tringali

  • Elisa Mauro

  • Calogero Vetro

  • Cinzia Maugeri

  • Marina Parisi

  • Bruno Garibaldi

  • Nicola Di Renzo

  • Claudia Romano

  • Domenico Pastore

  • Massimo Gentile

  • Ernesto Vigna

  • Carmine Selleri

  • Giuseppe Milone

  • uros markovic

Medical Centers

  • Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy

  • Hematology Unit AO Cosenza, Cosenza, Italy

  • Hematology, A. Perrino Hospital, Brindisi, Italy

  • Hematology and BMT Unit, Dipartimento di Specialità Medico-Chirurgiche- University of Catania, Catania, Italy

  • Onco-hematology department, Hematology Unit, Azienda Ospedaliera of Cosenza, Cosenza, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Oncology (ONC)

Disease

  • B-cell acute lymphoblastic leukemia

  • Epilepsy

Biomarkers

  • Cluster of Differentiation 19

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Levetiracetam

  • Blinatumomab

  • Methotrexate

  • ara-c

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved